Tecan's Trading Insights and Strategic Plans for 2024

Tecan's Trading Insights and Strategic Plans for 2024

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules

Tecan provides update on current trading and revised outlook for full year 2024

Current Challenges in Trading

Tecan Group, an innovator in laboratory automation, has recently provided insights into its current trading situation and an updated outlook for the fiscal year 2024. This update sheds light on several factors impacting its performance, particularly the substantial reductions in forecasts from OEM customers. These changes have emerged as critical elements affecting Tecan's outlook compared to previous expectations.

The Life Sciences Business division continues to encounter a demanding market environment while also demonstrating signs of sequential growth. Despite the ongoing challenges, Tecan is executing a rigorous cost-management program to navigate these turbulent times effectively.

Revised Outlook for 2024

Initially, Tecan had optimistic expectations for 2024, but recent developments have mandated a significant reassessment. Following the financial disclosures for the first half of the year, the company revealed that performance failed to meet anticipated benchmarks. Furthermore, order entries have not demonstrated the expected upticks.

Market Dynamics Affecting Performance

Key customers in the Partnering Business, particularly those with ties to life sciences instruments and exposure to markets like China, have deferred demands that could have driven growth this year. These delays have extensively impacted Tecan, as orders from the BioPharma sector in the Life Sciences division continue to lag.

Looking forward, Tecan currently forecasts a sales decline in local currencies between 12-14% for 2024. This represents a stark contrast to the earlier outlook, which anticipated minimal sales changes or slight decreases. In response to the lower sales volume, the company has modified its profitability expectations and initiated rigorous cost-reduction strategies. These steps will include restructuring to address cost inefficiencies and manage expenses prudently.

Market Conditions and Trends

The path ahead remains challenging for Tecan, primarily due to the ongoing market weaknesses in key regions like China. This slowdown has directly influenced both direct sales and collaborations via global OEM channels. As a result, spending in the biopharmaceutical industry has substantially decreased, leading to lowered demand for life science research tools.

Life Sciences Business Developments

In the Life Sciences sector, the lack of expected growth is a pressing concern. With the Chinese stimulus initiative unlikely to provide any immediate relief in 2024, Tecan is witnessing increased hesitancy among clients who are choosing to postpone orders while they assess financial situations.

However, amidst these trials, Tecan's Life Sciences business shows signs of recovery. Projecting only a moderate sales decline in the second half of the year compared to a 15.5% decline observed in the first half, Tecan is optimistic. The growing demand for consumables and services, especially those tied to newly launched clinical diagnostics products, has encouraged this positive outlook.

Future Strategies and Capital Markets Day

Despite the current hurdles, Tecan sees light at the end of the tunnel and anticipates steady growth as they approach their Capital Markets Day. This event will showcase Tecan's strategies aimed at capturing the upward trends in healthcare demands. The company will discuss their vision of returning to ideal organic growth levels in the mid to high single-digit percentage range once market conditions stabilize.

Operational Efficiencies and Innovations

With a solid record of market growth and consistent margin improvements, Tecan’s robust financial foundation inspires confidence in shareholders. By leveraging operational efficiencies and maintaining cost discipline, Tecan plans to enhance its adjusted EBITDA margins in line with their long-term objectives.

At the upcoming Capital Markets Day, Tecan will present innovative new products from its Life Sciences division, highlighting how the organization continues to lead in lab automation through significant technological advancements.

Important Dates Ahead

• The Capital Markets Day is scheduled for October 22, 2024.
• The Annual Report for 2024 will be published on March 12, 2025.
• Tecan’s shareholder Annual General Meeting is set for April 10, 2025.

About Tecan
Tecan is dedicated to enhancing global health through its groundbreaking approaches to laboratory automation. Established in Switzerland in 1980, Tecan is a leader in OEM development, manufacturing components, and medical devices through partnerships. With over 3,500 employees and a footprint in more than 70 countries, Tecan generated notable sales in recent years, solidifying its connected healthcare solutions for today's demands.

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Frequently Asked Questions

What are the main reasons for Tecan's revised outlook for 2024?

The revised outlook is primarily due to significant reductions in OEM customer forecasts and a lack of expected growth in the Life Sciences Business, especially with markets like China underperforming.

How is Tecan responding to the current market challenges?

Tecan is implementing a rigorous cost-down program to manage its financial health. This includes structural changes and stringent management of expenses to combat declining sales.

What does Tecan expect from the Capital Markets Day?

During the Capital Markets Day, Tecan plans to reaffirm its mid-term growth expectations and present upcoming innovations in their Life Sciences and Partnering Business units.

How has the performance in the Life Sciences sector changed?

Although the Life Sciences sector is facing challenges, it is expected to show only a moderate sales decline in the second half of 2024, indicating signs of recovery despite prior difficulties.

What financial performance does Tecan anticipate for 2024?

Tecan has adjusted its forecast to anticipate a decline in sales of 12-14% for the full year 2024, along with an adjusted EBITDA margin of 16-18% of sales.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.